Imkeldi access in the UAE: the EDE named-patient pathway
How patients in the United Arab Emirates legally obtain Imkeldi (imatinib oral solution) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Ask about Imkeldi in UAE
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Patients in the UAE access Imkeldi (imatinib oral solution) for chronic myeloid leukemia (CML) and Philadelphia-chromosome-positive acute lymphoblastic leukemia in adult and pediatric patients through the EDE named-patient pathway, an Emirates Drug Establishment-administered mechanism that allows a UAE-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and how to get a written quote.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
How Imkeldi reaches patients in the UAE
Imkeldi (imatinib oral solution, BCR-ABL tyrosine kinase inhibitor in a paediatric-friendly oral suspension formulation, FDA-approved May 2024 for chronic myeloid leukaemia in chronic phase, accelerated phase, or blast phase, and Philadelphia-chromosome-positive acute lymphoblastic leukaemia in adult and paediatric patients; the first FDA-approved oral solution of imatinib; marketed by Shorla Oncology) is not currently registered with MOHAP or EDE and is not visible on the MOHAP services portal at mohap.gov.ae/en/services as of 2026-05-31. UAE residents access Imkeldi through the EDE Permit to Import Medicines for Personal Use, the service transferred from MOHAP to EDE on 29 December 2025 per mohap.gov.ae/en/mte. The legal basis is Federal Law No. 8 of 2019. The Imkeldi-specific clinical justification must document: BCR-ABL1-positive CML or Ph+ ALL diagnosis (typically confirmed by quantitative RT-PCR or cytogenetics or FISH), patient age and weight-based dosing rationale (the suspension formulation is particularly relevant for paediatric or swallowing-impaired adult patients), prior imatinib-tablet experience or rationale for solution formulation (swallowing difficulty, paediatric dose-flexibility), and the prescribing oncology team's UAE-licensure status. EDE permits issue typically within several working days when documentation is complete.
Where Imkeldi is dispensed in the UAE
Imkeldi is dispensed in haematology, paediatric oncology, or general oncology outpatient settings with serial CBC, liver-function, and quantitative BCR-ABL transcript monitoring per the FDA label. Al Jalila Children's Specialty Hospital is the most-frequent paediatric-CML and Ph+-ALL referral nationally; CCAD and Ph+ ALL.
What Imkeldi costs in the UAE
Medicine price: quote on request. You get a written quote for your case before you commit. Do not estimate.
Funding and access barriers for Imkeldi in the UAE
Paediatric CML and Ph+ ALL are relatively rare; the UAE paediatric tertiary case load at Al Jalila, CCAD paediatric, and Tawam paediatric provides the clinical context. The historical standard for paediatric CML and Ph+ ALL has been crushed or compounded imatinib tablets (with quality-of-life and dosing-precision tradeoffs); Imkeldi's value is the FDA-approved oral solution formulation removing the compounding step. Public-sector funding: for Emirati national paediatric patients, Thiqa-administered Daman insurance at daman.ae covers specialty paediatric oncology at SEHA facilities; Dubai-resident Emirati nationals on Salama or ENAYA receive comparable cover. MOHAP-administered free care applies in the Northern Emirates. Institutional formulary committees adjudicate Imkeldi versus continued generic imatinib compounding case-by-case. The Patient Affairs Department and Mohammed bin Rashid Foundation may grant funding for difficult cases. Major insurers (Daman, Bupa Arabia, AXA Gulf, MetLife, Sukoon, Cigna, Allianz, Mednet, Nextcare, NAS) require prior authorisation with documented inability to use crushed-tablet preparation or paediatric weight-band documentation. Out-of-pocket exposure is most material for expatriate paediatric oncology families. Shorla Oncology operates a patient-support programme at early-launch stage in 2026.
Recent regulatory and access news for Imkeldi
FDA approved Imkeldi (imatinib oral solution) on 10 May 2024 for CML in chronic, accelerated, or blast phase, and Ph+ ALL in adult and paediatric patients; the first FDA-approved oral solution of imatinib. The FDA approval letter is at accessdata.fda.gov/scripts/cder/daf. EMA pathway for the oral solution has not been formally announced at scale by Shorla Oncology as of 2026-05-31; check the EMA medicines database at ema.europa.eu/en/medicines for status. MOHAP transferred personal-use import permit service to EDE on 29 December 2025 per mohap.gov.ae/en/mte; UAE Imkeldi personal-import applications now route through ede.gov.ae. No MOHAP or EDE bulletin specific to Imkeldi has been observed.
Where Reserve Meds fits in Imkeldi cases
Reserve Meds is a US-based digital health company. We do not replace your treating physician, we do not replace EDE, and we do not replace your dispensing pharmacy. For Imkeldi specifically, we orchestrate supply through a US-licensed pharmaceutical wholesale partner, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into the UAE, and give you one point of contact through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Imkeldi case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the EDE application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the case coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Imkeldi's oral-solution presentation fills a real pediatric and dysphagia gap; the named-patient case typically rests on documented inability to swallow the standard tablet form of imatinib. UAE specialty referral typically routes these cases through Abu Dhabi or Dubai tertiary centres.
Next step
If your UAE physician has prescribed Imkeldi and you are weighing the cross-border route, the next step is a short intake. We reply within one business day, then send a documentation checklist to your doctor.
Reserved for you.